Supporting this, they found increased caspase-1 activation and IL-1β production in CMML, juvenile myelomonocytic leukemia (JMML) and AML patients with KRAS mutations as compared to patients without KRAS mutations (Hamarsheh et al., 2020). This evidence concerns the gene KRAS and juvenile myelomonocytic leukemia.